2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3017 Immature platelet fraction as a surrogate marker of hypocoagulable rotational thromboelastometry and major bleeding in thrombocytopenic patients

Alexandre Eiji Eiji Kayano, MD, Afonso Cardoso, MD2, Giane Durigon, MD3, Newton de Freitas Centurião, Newton Centurião4, Rodrigo Seiti Kojima, MD5, Liliana Mitie Suganuma, MD6, Andreza Oliveira dos Santos, MS7, Cristina Mariko Ito8, Andrea Rocco Villarinho, N/A9, João Carlos de Campos Guerra, MD10
1 Einstein Hospital Israelita, São Paulo, SP, Brazil
2 Einstein Hospital Israelita, São Paulo, SP, Brazil
3 Einstein Hospital Israelita, São Paulo, SP, Brazil
4 Einstein Hospital Israelita, São Paulo, SP, Brazil
5 Einstein Hospital Israelita, São Paulo, SP, Brazil
6 Einstein Hospital Israelita, São Paulo, SP, Brazil
7 Einstein Hospital Israelita, São Paulo, SP, Brazil
8 Einstein Hospital Israelita, São Paulo, SP, Brazil
9 Einstein Hospital Israelita, São Paulo, SP, Brazil
10 Einstein Hospital Israelita, São Paulo, SP, Brazil

Introduction

Bleeding in thrombocitopenic patients is difficult to predict. Rotational thromboelastometry (ROTEM) is a well-established viscoelastic assay for bleeding assessment in several clinical settings, with increasing evidence supporting its use in this scenario.

Immature platelet fraction (IPF) is an indirect measure of newly released platelets obtained by assessing platelet RNA content using fluorescent dye-based testing on hematologic analyzers. Acute bleeding is expected to increase platelet consumption and stimulate thrombopoiesis, leading to elevated IPF levels. As the literature of this association is scarce, our objective is to evaluate association between lower IPF with hypocoagulable ROTEM and major bleeding in thrombopenic patients. 

Methods

This retrospective study evaluated laboratory data and medical records from a tertiary care hospital collected sequentially between Feb 2020 and May 2026. All laboratory analyses were performed using the Sysmex XN-10® hematology and the ROTEM delta® hemostasis analyzers.

The analysis was restricted to patients with platelet counts <100,000/μL and normal coagulation profile and fibrinogen levels. Major bleeding was defined as fatal bleeding, bleeding occurring in a critical organ, or bleeding resulting in a hemoglobin decrease of ≥2 g/dL or requiring transfusion of ≥2 units of packed red blood cells after laboratory collection. ROTEM was classified as hypocoagulable when EXTEM demonstrated MCF<50 mm and/or CFT>159 seconds or INTEM demonstrated MCF<50 mm and/or CFT>110 seconds, with FIBTEM MCF>9 mm. Among 2053 ROTEM examinations, 175 met the inclusion criteria.

Continuous variables were summarized as means ± standard deviations or medians (IQR), and categorical variables as frequencies and percentages. Pearson's test assessed the correlation between MPV and IPF. Hypocoagulable ROTEM and major bleeding were defined as the primary outcomes, whereas age, sex, platelet count, mean platelet volume (MPV), IPF, history of liver disease, creatinine clearance, oncologic history, and use of antiplatelet agents were considered explanatory variables. Comparisons between groups were performed using the Student's t-test, Mann-Whitney U test, chi-square test, and multivariable binary logistic regression. Statistical significance was defined as p < 0.05. All statistical analyses were performed using R software (version 4.2.1).

Results

The study population consisted predominantly of men (n = 115/175), with a median age of 62.7 years. MPV showed a moderate correlation with IPF. This finding was expected, as MPV has historically been considered an unreliable marker for bleeding risk evaluation, whereas IPF has emerged as a promising biomarker for this purpose.

Compared with patients with normal ROTEM, those with hypocoagulable ROTEM had significantly lower platelet counts (50,272.73 [IQR 27,875.23] vs. 70,569.77 [IQR 21,261.70], p<0.001) and lower IPF (6.22 [IQR 4.13] vs. 9.88 [IQR 6.29], p<0.001), whereas no significant differences were observed regarding age, sex, MPV, liver disease, creatinine clearance, oncologic history, or antiplatelet therapy. In multivariable analysis, both platelet count (OR=1.78, 95% CI 1.34-2.56, p<0.001) and IPF (OR=1.33, 95% CI 1.11-1.64, p=0.006) remained independently associated with hypocoagulable ROTEM. These findings suggest that IPF may serve as an early surrogate marker of hypocoagulable ROTEM, which is particularly relevant given the limited availability of ROTEM in most healthcare centers.

Importantly, major bleeding was independently associated  in multivariable analysis only with hypocoagulable ROTEM  (OR=25.2, 95% CI 6.61-127.46, p<0.001) and lower IPF (OR=1.08, 95% CI 1.01-1.18, p=0.04). A 2014 study by Greene et al. demonstrated that both IPF and thromboelastometry are useful tools in the management of children with immune thrombocytopenic purpura because of their association with bleeding risk. Our findings reinforce the value of IPF and ROTEM in assessing bleeding risk among thrombocytopenic patients. Furthermore, to our knowledge, this is the first study to demonstrate their applicability in a heterogeneous population of patients with multiple comorbidities, including chronic kidney disease, chronic liver disease, and malignancies. 

Conclusion

In addition to lower platelet counts, IPF may serve as a surrogate marker for hypocoagulable ROTEM and, more importantly, is associated with an increased risk of major bleeding in thrombocytopenic patients.

Alexandre Eiji Eiji Kayano, MD: No relevant conflicts of interest to declare.